

# Barriers to Care in Migraine in Germany

**First published:** 01/12/2021

**Last updated:** 23/04/2024

Study

Finalised

## Administrative details

### EU PAS number

EUPAS44516

---

### Study ID

50348

---

### DARWIN EU® study

No

---

### Study countries

 Germany

---

### Study description

The study is a prospective anonymous cross-sectional study using a web-based survey. Participants with headache are eligible to enter the survey. First step will be a screening for potential migraine using the ID-Migraine™ questionnaire. Participants will be subsequently stratified to three different

questionnaires based on their potential migraine diagnosis not made by a physician (survey1), migraine with a medical diagnosis (without preventive medication experience) (survey 2), migraine with medical diagnosis (with preventive medication experience) (survey 3). The study will address the impact of potential predictors of barriers to migraine

---

### **Study status**

Finalised

## Contact details

### **Study institution contact**

Fleischmann Robert [robert.fleischmann@uni-greifswald.de](mailto:robert.fleischmann@uni-greifswald.de)

**Study contact**

[robert.fleischmann@uni-greifswald.de](mailto:robert.fleischmann@uni-greifswald.de)

### **Primary lead investigator**

Fleischmann Robert

**Primary lead investigator**

## Study timelines

### **Date when funding contract was signed**

Planned: 17/06/2021

Actual: 17/06/2022

---

### **Study start date**

Planned: 02/12/2021

Actual: 02/12/2022

---

## **Date of final study report**

Planned: 01/12/2022

Actual: 03/01/2023

## Sources of funding

- Pharmaceutical company and other private sector

## More details on funding

Teva GmbH

## Regulatory

### **Was the study required by a regulatory body?**

No

---

### **Is the study required by a Risk Management Plan (RMP)?**

Not applicable

## Methodological aspects

### Study type

### Study type list

### **Study topic:**

Disease /health condition

---

**Study type:**

Non-interventional study

---

**Scope of the study:**

Disease epidemiology

Effectiveness study (incl. comparative)

**Data collection methods:**

Primary data collection

---

**Main study objective:**

To explore the proportion of patients with migraine symptoms undiagnosed by physician

## Study Design

**Non-interventional study design**

Cross-sectional

## Study drug and medical condition

**Medical condition to be studied**

Headache

Migraine

## Population studied

## **Short description of the study population**

A web-based survey of participants with headache in Germany.

---

### **Age groups**

- Adults (18 to < 46 years)
  - Adults (46 to < 65 years)
  - Adults (65 to < 75 years)
  - Adults (75 to < 85 years)
  - Adults (85 years and over)
- 

### **Special population of interest**

Other

---

### **Special population of interest, other**

Patients with headaches and migraine headaches

---

### **Estimated number of subjects**

10000

## **Study design details**

### **Outcomes**

percentage of pts with migraine symptoms undiagnosed by physician, To explore the difference in distribution of the variables of interest in patients diagnosed with migraine and no prophylactic treatment and patients diagnosed with migraine and prophylactic treatment for guideline-guided therapy To explore the difference in distribution of the variables in subset of patients who qualify for prophylactic treatment in group 2 for guideline-guided therapy

versus

---

### **Data analysis plan**

All variables will be summarized descriptively. For continuous variables, descriptive statistics (n, mean, standard deviation, standard error of mean, median, minimum, and maximum) will be provided. For categorical variables, frequency and percentage will be provided. The 95% confidence intervals will be provided for point estimate, if appropriate. Regression models will be employed to provide an estimate of the predictive value of endpoints for being correctly diagnosed with migraine and/or the use of an indicated preventive medication.

## Data management

### ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

## Data sources

### **Data sources (types)**

[Other](#)

---

### **Data sources (types), other**

Prospective patient-based data collection

## Use of a Common Data Model (CDM)

## **CDM mapping**

No

## Data quality specifications

### **Check conformance**

Unknown

---

### **Check completeness**

Unknown

---

### **Check stability**

Unknown

---

### **Check logical consistency**

Unknown

## Data characterisation

### **Data characterisation conducted**

No